See leaflet
Signum®
decitabine
Indications
- Adult patients with Myelodysplastic Syndromes (MDS)
- Previously treated and untreated, de novo and secondary Myelodysplastic Syndromes of all French-AmericanBritish subtypes
- Intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups.
Presentations
- 50 mg x 1 vial
- 50 mg x 1 vial